RxDoctor Payments Data

Jennifer Dunham, NP

Nurse Practitioner · Charlotte, NCNPI 1821338443

Payments from drug & device makers

$6,694in general payments, 2019–2025

Across 352 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$739
  • Lilly USA, LLC$674
  • AbbVie$565
  • Novo Nordisk$506
  • AstraZeneca$465
  • Viiv Healthcare Company$379
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,694100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,694 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$48,520
Medicare patients
209
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol18$24,693
JardianceEmpagliflozin15$17,979
EliquisApixaban20$16,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$16,134
Tresiba Flextouch U-200Insulin Degludec20$13,244
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$9,632
BelsomraSuvorexant13$8,353
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,136
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,222
Albuterol Sulfate HfaAlbuterol Sulfate94$1,779
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide54$1,315
Amlodipine Besylate259$1,181
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$1,089
Pravastatin Sodium74$1,049
Atorvastatin Calcium128$1,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$465$24,69318 claims
GSKTrelegy Ellipta, Anoro Ellipta$181$21,27033 claims
Boehringer IngelheimJardiance$190$17,97915 claims
PfizerEliquis$368$16,23120 claims
MerckBelsomra$167$8,35313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →